文献速递心力衰竭与心肌病

心力衰竭最佳血清钾浓度:个体患者数据荟萃分析

Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.
PubMed 文献 · Eur Heart J · 2026-01-01

结果显示HFrEF中血钾与结局呈反向J型关联,低钾血症与全因死亡风险升高相关;HFrEF和HFpEF的最低风险均见于基线血钾4.2-5.0 mmol/L。

要点

  • HFrEF患者血钾<3.5 mmol/L与全因死亡风险升高相关,应避免低钾血症。
  • HFrEF和HFpEF患者最低结局风险均见于基线血钾4.2-5.0 mmol/L。
  • HFrEF中轻度高钾血症(5.0-5.5 mmol/L)未与更差结局相关。

核心结论

  • HFrEF中低钾血症与更差结局强相关,应避免。
  • 就安全性而言,HFrEF和HFpEF的最佳血清钾浓度范围均似为4.2-5.0 mmol/L。

研究设计与样本

  • 来自12项随机对照试验的个体患者数据汇总分析。
  • 基线血清钾分为六组(<3.5、≥3.5-<4.0、≥4.0-<4.5、≥4.5-<5.0、≥5.0-<5.5、≥5.5 mmol/L),并以限制性立方样条作为连续变量分析。
  • 主要结局为全因死亡,次要结局包括心血管死亡、猝死、泵衰竭死亡、首次心衰住院及心衰住院与心血管或全因死亡的复合终点。

主要发现

  • HFrEF和HFpEF试验的中位随访时间分别为24.2和36.8个月。
  • HFrEF中血清钾与结局呈反向J型关联。
  • 与≥4.0-4.5 mmol/L(参照)相比,血钾<3.5 mmol/L与更高的全因死亡风险相关(校正风险比1.49;95%CI 1.27-1.76),以及心血管、猝死和泵衰竭死亡风险。
  • HFrEF中所有结局的最低风险见于基线血清钾4.2-5.0 mmol/L范围,但轻度高钾血症(5.0-5.5 mmol/L)未与更差结局相关。
  • HFpEF中风险曲线呈U型且更平坦,但所有结局的最低发生率见于与HFrEF相同的血钾范围。

临床怎么用

  • HFrEF患者应避免低钾血症(<3.5 mmol/L)。
  • HFrEF和HFpEF患者血钾管理目标可考虑4.2-5.0 mmol/L范围。
  • HFrEF中轻度高钾血症(5.0-5.5 mmol/L)未显示与更差结局相关,无需过度担忧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: It remains unclear what the safe serum potassium range is in heart failure (HF) and whether it is the same in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). METHODS: A patient-level pooled analysis from 12 randomized controlled trials including 32 346 HFrEF and 13 723 HFpEF patients was performed. Baseline serum potassium level was categorized into six groups (<3.5, ≥3.5-<4.0, ≥4.0-<4.5, ≥4.5-<5.0, ≥5.0-<5.5, and ≥5.5 mmol/L) and serum potassium level at baseline was also analysed as a continuous variable using restricted cubic splines. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, sudden death, pump failure death, first HF hospitalization, and composites of HF hospitalization and cardiovascular or all-cause death. RESULTS: The median follow-up was 24.2 and 36.8 months in HFrEF and HFpEF trials, respectively. In HFrEF, serum potassium levels showed a reverse J-shaped association with outcomes. Compared with ≥4.0-4.5 mmol/L (reference), potassium <3.5 mmol/L was associated with higher risks of all-cause mortality (adjusted hazard ratio 1.49; 95% confidence interval, 1.27-1.76), as well as cardiovascular, sudden, and pump failure death. The lowest risk for all outcomes was observed within the baseline serum potassium range of 4.2-5.0 mmol/L, but even 'mild hyperkalaemia' (5.0-5.5 mmol/L) was not associated with worse outcomes in HFrEF. Although the risk curve was U-shaped and flatter in HFpEF, the lowest incidence of all outcomes was observed over the same potassium range as HFrEF. CONCLUSION: In HFrEF, hypokalaemia is strongly associated with worse outcomes and should be avoided. In terms of safety, the optimal serum potassium concentration in both HFrEF and HFpEF appears to be in the range 4.2-5.0 mmol/L.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ono, Chimura, Docherty, et al. Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis. Eur Heart J. 2026. PMID: 42206478. doi:10.1093/eurheartj/ehag341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。